Lv5
1570 积分 2024-08-15 加入
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
1个月前
已完结
International uniform response criteria for multiple myeloma
1个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2个月前
已完结
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
2个月前
已完结
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
3个月前
已完结
Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy
3个月前
已完结
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio
3个月前
已完结
Paediatric‐onset Evans syndrome: Breaking away from refractory immune thrombocytopenia
4个月前
已关闭
Systemic Light Chain Amyloidosis
4个月前
已完结
Systemic Light Chain Amyloidosis
4个月前
已关闭
皖公网安备34019202002308
